Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 311

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Maître, M., Aractingi, S., Bachelez, H., Cribier, B., Joly, P., Jullien, D., Misery, L., Paul, C., Ortonne, J.‐P., Richard, M.‐A.·2012·Journal of the European Academy of Dermatology and Venereology

Abstract

Background Oral 8‐methoxypsoralen–UV‐A (PUVA) and narrowband UV‐B (NB‐UVB or UVB TL‐01) are effective and widely used treatments for chronic plaque psoriasis. Although the role of PUVA therapy in skin carcinogenesis in humans with psoriasis has been clearly demonstrated, there is still controversy regarding the risk of skin cancer with NB‐UVB. Furthermore, there is no clear evidence about the maximum cumulative number of sessions not to be exceeded in a lifetime. Objectives To assess the respective cutaneous carcinogenic risks of PUVA or NB‐UVB in psoriasis; to estimate the respective dose‐relationship between skin cancers and PUVA or NB‐UVB; to estimate a maximum number of sessions for PUVA or NB‐UVB not to be exceeded in a lifetime. Methods A systematic literature search was carried out in Medline, Embase and Cochrane Library databases from1980 to December 2010 in English and French, with the keywords ‘Psoriasis’ AND ‘UVB therapy’ AND ‘UVA therapy’ AND ‘cancer’ AND ‘skin’ OR ‘neoplasm’ OR ‘cutaneous carcinoma’ OR ‘melanoma’. Results Of 243 identified references, 49 published studies were included. Most of them (45/49) concerned PUVA therapy, with 41 assessing the risk of non‐melanoma skin cancers (NMSC) following PUVA. All publications referring to the US prospective PUVA follow‐up study revealed an increased risk of NMSC with the following characteristics: risk most pronounced for squamous cell carcinomas developing even with low exposures and increasing linearly with the number of sessions, tumors occurring also on non‐exposed skin including invasive penile tumors, risk persisting after cessation of treatment. An increased risk of basal cell carcinomas was observed in patients receiving more than hundred PUVA sessions. The four prospective European studies selected in our review and most of the pre‐1990 European and US retrospective studies failed to find a link between exposure to PUVA and skin cancer. Only the most recent cohorts, including three large long‐term retrospective European studies comparing records with their respective national cancer registries reported on an independent increased risk of NMSC with PUVA, The risk was lower as compared to the US prospective PUVA follow‐up study. Six studies assessed the risk of melanoma following PUVA therapy: two of the three US publications coming from the same PUVA prospective follow‐up study revealed an increased risk with more than doubled incidence of both invasive and in situ melanoma among patients exposed to at least 200 PUVA treatments compared with patients exposed to lower doses, whereas the three retrospectives European studies, comparing the incidence of melanoma in PUVA users with national cancer registers, did not find any increased risk of melanoma. No increased risk of skin cancer was evidenced in the four studies specifically assessing the potential carcinogenic risk of NB‐UVB Conclusion There is an increased risk of skin cancer following PUVA, shown by both US and European studies. The greater risk measured by the US studies may be at least partly explained by high UVA dose exposure and the lighter phototypes of the treated patients. The lack of prospective studies in psoriasis patients treated with NB‐UVB constitutes a barrier to the robust assessment of carcinogenic risk of this phototherapy technique.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-3083.2012.04520.x

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 311

Metadata

Authors
Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Maître, M., Aractingi, S., Bachelez, H., Cribier, B., Joly, P., Jullien, D., Misery, L., Paul, C., Ortonne, J. ‐., & Richard, M. ‐.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2012-04-18
Volume
26
Issue
s3
Pages
22-31
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W2169053128
Cited by
311
References
46
FWCI
1.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. https://app.cochat.ai/papers/10.1111/j.1468-3083.2012.04520.x
The paper
Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Maître, M., Aractingi, S., Bachelez, H., Cribier, B., Joly, P., Jullien, D., Misery, L., Paul, C., Ortonne, J. ‐., & Richard, M. ‐. (2012). Carcinogenic risks of Psoralen UV‐A therapy and Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/j.1468-3083.2012.04520.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.